Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics

<b>Background</b>: TV-44749 is a subcutaneous (sc) long-acting injectable (LAI) formulation of olanzapine that recently demonstrated efficacy and safety as a treatment for schizophrenia in adults without the occurrence of post-injection delirium/sedation syndrome (PDSS) in the phase 3 SOLARIS trial...

Celý popis

Podrobná bibliografie

Hlavní autoři:	David Bibi, Lilach Steiner, Iva Krtalic, Marina Juretic, Biserka Cetina-Cizmek, Andrea Komlosi, Pippa Loupe, Kristina Ferderber, Hussein Hallak
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-05-01
Edice:	Pharmaceutics
Témata:	olanzapine long-acting injectable TV-44749 schizophrenia post-injection delirium/sedation syndrome (PDSS)
On-line přístup:	https://www.mdpi.com/1999-4923/18/5/601
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!